NasdaqGM - Nasdaq Real Time Price USD
Nurix Therapeutics, Inc. (NRIX)
9.30
-0.35
(-3.58%)
At close: May 7 at 4:00:00 PM EDT
9.30
0.00
(0.00%)
After hours: May 7 at 4:49:35 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (May 2025) | Next Qtr. (Aug 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 15 | 15 | 15 | 14 |
| Avg. Estimate | -0.76 | -0.8 | -3.08 | -3.31 |
| Low Estimate | -0.96 | -0.99 | -3.56 | -4.6 |
| High Estimate | -0.6 | -0.7 | -2.79 | -1.62 |
| Year Ago EPS | -0.71 | -0.67 | -2.88 | -3.08 |
Revenue Estimate
| Currency in USD | Current Qtr. (May 2025) | Next Qtr. (Aug 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 16 | 16 | 17 | 16 |
| Avg. Estimate | 16.28M | 14.42M | 63.14M | 65.94M |
| Low Estimate | -- | -- | 18.5M | -- |
| High Estimate | 33.64M | 20M | 89.28M | 212.53M |
| Year Ago Sales | 12.09M | 12.59M | 54.55M | 63.14M |
| Sales Growth (year/est) | 34.60% | 14.57% | 15.75% | 4.44% |
Earnings History
| Currency in USD | 5/31/2024 | 8/31/2024 | 11/30/2024 | 2/28/2025 |
|---|---|---|---|---|
| EPS Est. | -0.63 | -0.68 | -0.67 | -0.76 |
| EPS Actual | -0.71 | -0.67 | -0.75 | -0.67 |
| Difference | -0.08 | 0.01 | -0.08 | 0.09 |
| Surprise % | -11.86% | 1.84% | -12.13% | 12.00% |
EPS Trend
| Currency in USD | Current Qtr. (May 2025) | Next Qtr. (Aug 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.76 | -0.8 | -3.08 | -3.31 |
| 7 Days Ago | -0.76 | -0.81 | -3.09 | -3.32 |
| 30 Days Ago | -0.78 | -0.8 | -3.14 | -3.24 |
| 60 Days Ago | -0.77 | -0.78 | -3.1 | -3.2 |
| 90 Days Ago | -0.76 | -0.78 | -3.09 | -3.13 |
EPS Revisions
| Currency in USD | Current Qtr. (May 2025) | Next Qtr. (Aug 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 9 | 6 | 8 | 6 |
| Up Last 30 Days | 8 | 6 | 8 | 5 |
| Down Last 7 Days | 2 | 5 | 4 | 3 |
| Down Last 30 Days | 2 | 4 | 4 | 3 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| NRIX | -7.19% | -20.06% | -7.00% | -7.49% |
| S&P 500 | 12.50% | 3.24% | 7.95% | 13.84% |
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/29/2025 |
| Maintains | Wells Fargo: Overweight to Overweight | 4/9/2025 |
| Maintains | Stifel: Buy to Buy | 4/9/2025 |
| Maintains | Needham: Buy to Buy | 4/9/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/2/2025 |
| Initiated | Leerink Partners: Market Perform | 3/17/2025 |
Related Tickers
KYMR Kymera Therapeutics, Inc.
29.11
+1.89%
ITOS iTeos Therapeutics, Inc.
6.44
-2.72%
ORIC ORIC Pharmaceuticals, Inc.
4.7000
-6.75%
ALXO ALX Oncology Holdings Inc.
0.4841
-3.89%
XNCR Xencor, Inc.
7.99
-5.61%
KURA Kura Oncology, Inc.
5.65
-2.50%
CCCC C4 Therapeutics, Inc.
1.5000
+6.38%
RLAY Relay Therapeutics, Inc.
2.9500
-6.35%
NUVL Nuvalent, Inc.
66.72
-2.16%
IDYA IDEAYA Biosciences, Inc.
17.83
+0.45%